Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1978 Jan;31(1):12–15. doi: 10.1136/jcp.31.1.12

Specific and non-specific resistance to aminoglycosides in Escherichia coli.

S L Mawer, D Greenwood
PMCID: PMC476711  PMID: 342544

Abstract

The turbidimetric responses of a strain of Escherichia coli K12 to gentamicin and tobramycin were investigated. Both agents showed antibacterial activity below the conventionally measured minimum inhibitory concentration, but exposure to such subinhibitory concentrations of either agent generated a bacterial population which was able to grow in previously inhibitory concentrations at a rate equivalent to that of the parent culture. The increase in resistance was non-specific in that both aminoglycosides were equally affected, and was unstable on multiple passage in drug-free broth. The response to tobramycin was unaffected by the presence of an R factor conferring gentamicin resistance, but exposure of the R factor bearing strain to gentamicin caused a concomitant increase in the resistance to tobramycin, apparently by a non-specific adaptive mechanism similar to that observed with the parent strain. It is suggested that prior treatment of a gentamicin-resistant organism with gentamicin (as may occur during blind therapy) may adversely affect the subsequent response to other aminoglycosides.

Full text

PDF
13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benveniste R., Davies J. Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem. 1973;42:471–506. doi: 10.1146/annurev.bi.42.070173.002351. [DOI] [PubMed] [Google Scholar]
  2. Greenwood D., O'Grady F. Comparison of the responses of Escherichia coli and proteus mirabilis to seven beta-lactam antibodies. J Infect Dis. 1973 Aug;128(2):211–222. doi: 10.1093/infdis/128.2.211. [DOI] [PubMed] [Google Scholar]
  3. Hedges R. W., Rodriguez-Lemoine V., Datta N. R factors from Serratia marcescens. J Gen Microbiol. 1975 Jan;86(1):88–92. doi: 10.1099/00221287-86-1-88. [DOI] [PubMed] [Google Scholar]
  4. Houang E. T., Greenwood D. Aminoglycoside cross-resistance patterns of gentamicin-resistant bacteria. J Clin Pathol. 1977 Aug;30(8):738–744. doi: 10.1136/jcp.30.8.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Mackintosh I. P., O'Grady F., Greenwood D., Watson B. W., Crichton T. C., Piper R., Ferrer A. A twelve channel bacterial growth monitoring system. Biomed Eng. 1973 Dec;8(12):514–passim. [PubMed] [Google Scholar]
  6. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Waterworth P. M. The in-vitro activity of tobramycin compared with that of other aminoglycosides. J Clin Pathol. 1972 Nov;25(11):979–983. doi: 10.1136/jcp.25.11.979. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES